**Background of PAX5 Antibody**
PAX5. a member of the PAX (paired box) transcription factor family, is critical for B-cell development and commitment. It regulates genes involved in B-cell receptor signaling, adhesion, and migration, ensuring proper differentiation and function. PAX5 is expressed during early B-cell ontogeny and persists in mature B-cells but is absent in plasma cells.
In diagnostic pathology, PAX5 antibodies are widely used as immunohistochemical (IHC) markers to identify B-cell lineage in malignancies. PAX5 expression is retained in most B-cell neoplasms, including B-acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphomas (NHLs). Its nuclear staining pattern helps distinguish B-cell tumors from T-cell or myeloid malignancies. PAX5 is particularly valuable in differentiating classical Hodgkin lymphoma (cHL), where PAX5 is weakly expressed in Hodgkin-Reed-Sternberg (HRS) cells, from other large B-cell lymphomas.
PAX5 antibodies target the N-terminal DNA-binding domain of the protein. Loss of PAX5 expression or mutations are linked to B-cell maturation arrest and leukemogenesis, underscoring its role as a tumor suppressor in some contexts. However, aberrant PAX5 activity can also drive oncogenic pathways in specific cancers.
Research and clinical applications rely on PAX5 antibodies for studying B-cell biology, disease mechanisms, and refining diagnostic accuracy in hematopathology. Its specificity makes it a cornerstone in panels alongside CD20. CD79a, and other markers.